KCM
PLX icon

Kennedy Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Kennedy Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-149,151
Closed -$577K – 693
2020
Q3 		$577K Buy
149,151
+47,764
+47% +$173K 0.02% 583
2020
Q2 		$384K Buy
+101,387
New +$347K 0.01% 616

Other funds holding PLX

BCM
Burrage Capital Management Boston, Massachusetts $99.7M AUM 66.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Kennedy Capital Management's PLX Position: Q4 2020 in Review

Kennedy Capital Management sold out of Protalix BioTherapeutics (PLX) in Q4 2020, closing a stake of 149,151 shares — an estimated $577K sold.

Kennedy Capital Management first reported a position in PLX in Q2 2020 and held it in 2 quarters. The position peaked at $577K in Q3 2020. 23 funds tracked by Wall St. Rank hold PLX as of Q4 2020.

  • Kennedy Capital Management reported no remaining Protalix BioTherapeutics position as of Q4 2020 after selling out during the quarter.
  • Kennedy Capital Management sold 149,151 Protalix BioTherapeutics shares in Q4 2020, an estimated $577K.
  • Kennedy Capital Management first reported a position in Protalix BioTherapeutics in Q2 2020 and held it in 2 quarters.
  • Kennedy Capital Management's Protalix BioTherapeutics position peaked at $577K in Q3 2020.
  • 23 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2020.

Based on Kennedy Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.